Neanderthal Enzyme's Impact on Athletic Performance and Health
Deep within our muscles, an enzyme called AMPD1 plays a crucial role in converting chemical fuel into usable energy. When it malfunctions, muscles fatigue more quickly. This is significant because AMPD1 issues are the most prevalent genetic cause of metabolic muscle disease in Europe, affecting up to 14% of individuals. A recent study published in Nature Communications reveals that a weakened version of this enzyme can be traced back to Neanderthals, offering insights into its influence on strength, stamina, and health.
The Neanderthal Enzyme Variant
The study, involving researchers from the Max Planck Institute for Evolutionary Anthropology, compared ancient Neanderthal DNA with modern human genomes. They discovered that every Neanderthal carried a unique AMPD1 change, not found in any other primate species. This small genetic alteration has significant implications. When the Neanderthal enzyme was recreated in a lab, its activity was reduced by approximately 25% compared to the modern human version. Further experiments with mice engineered to carry the same change showed an 80% decrease in enzyme activity in muscle tissue, confirming the Neanderthal variant's reduced efficiency.
Impact on Athletic Performance
Dominik Macak, the study's lead author, noted that while most individuals carrying the variant don't experience significant health issues, the enzyme plays a crucial role in athletic performance. The research team, which included geneticists studying human evolution and muscle biology, found that elite athletes were less likely to carry the AMPD1 variants that reduce enzyme function. Macak stated that carrying a defective AMPD1 enzyme halves the likelihood of achieving athletic performance.
This effect was observed in both endurance sports, such as distance running, and power sports, like weightlifting. The enzyme's role becomes more critical under extreme physical stress, where it may not be as significant in everyday conditions.
Health Implications Beyond Sports
The study also explored medical records from large biobanks, revealing a slightly increased risk of vein problems, including varicose veins, in individuals with reduced AMPD1 activity. While the risk was modest, ranging from three to six percent, it was consistently observed across datasets. Additionally, a few rare individuals with two different damaging AMPD1 variants reported chronic muscle pain, cramps, and exercise intolerance, suggesting that the enzyme becomes crucial when its activity drops too low.
Evolutionary Perspective
The researchers believe that AMPD1 faced relaxed evolutionary pressure in both Neanderthals and modern humans. Hugo Zeberg, a senior author, proposed that cultural and technological advancements may have reduced the need for extreme muscle performance, allowing variants that reduce AMPD1 activity to persist without significant harm. Better tools, cooperation, and food strategies likely lowered the survival cost of weaker muscle energy systems.
Practical Applications and Future Directions
This research highlights the value of studying ancient DNA to understand modern differences in strength, endurance, and disease risk. It explains why some individuals struggle with intense exercise while remaining healthy in daily life. For medicine, it provides insights into muscle disorders and vein disease. Additionally, it emphasizes the importance of studying genes in both evolutionary and physiological contexts to fully comprehend their impact.
The study also invites further exploration of Neanderthal DNA's role in shaping the modern human face, the timing of human-Neanderthal interbreeding, and the link between Neanderthal DNA and autism.
